IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof- of-concept study K. Grothe, K. Flechsenhar, T. Paehler, O. Ritzeler, J. Beninga, J. Saas, M. Herrmann, K. Rudolphi Osteoarthritis and Cartilage Volume 25, Issue 1, Pages 46-52 (January 2017) DOI: 10.1016/j.joca.2016.08.010 Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 1 Illustration of the mode of action of the IKK-inhibitor SAR113945. Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 2 Graphic illustration of the concentration of SAR113945 in the plasma of study participants. Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 3 Relative Change [%] from baseline from Day 1 to Day 168 – Mean (±SEM). Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 4 Relative Change [%] from baseline from Day 1 to Day 168 – Mean (±SEM). Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 5 Graphic illustration of the concentration of SAR113945 in the plasma of study participants. Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions
Fig. 6 Illustration of concentrations of SAR113945 in plasma in study participants depending on the subgroup of patients, i.e., those with knee effusion at baseline and those without effusion. Osteoarthritis and Cartilage 2017 25, 46-52DOI: (10.1016/j.joca.2016.08.010) Copyright © 2016 Osteoarthritis Research Society International Terms and Conditions